LinkedIn

 آمار

تعداد نشریات20
تعداد شماره‌ها1,113
تعداد مقالات10,208
تعداد مشاهده مقاله40,779,956
تعداد دریافت فایل اصل مقاله8,803,880
Aali, Ehsan, Ghaznavi, Habib, Soltanpour, Mohammad Soleiman, Mahmoudian, Massoud, Shafiei, Massoumeh. (1399). Cardioprotective Effects of Mebudipine in a Rat Model of Doxorubicin-Induced Heart Failure. سامانه مدیریت نشریات علمی, 46(2), 136-143. doi: 10.30476/ijms.2019.82057.0
Ehsan Aali; Habib Ghaznavi; Mohammad Soleiman Soltanpour; Massoud Mahmoudian; Massoumeh Shafiei. "Cardioprotective Effects of Mebudipine in a Rat Model of Doxorubicin-Induced Heart Failure". سامانه مدیریت نشریات علمی, 46, 2, 1399, 136-143. doi: 10.30476/ijms.2019.82057.0
Aali, Ehsan, Ghaznavi, Habib, Soltanpour, Mohammad Soleiman, Mahmoudian, Massoud, Shafiei, Massoumeh. (1399). 'Cardioprotective Effects of Mebudipine in a Rat Model of Doxorubicin-Induced Heart Failure', سامانه مدیریت نشریات علمی, 46(2), pp. 136-143. doi: 10.30476/ijms.2019.82057.0
Aali, Ehsan, Ghaznavi, Habib, Soltanpour, Mohammad Soleiman, Mahmoudian, Massoud, Shafiei, Massoumeh. Cardioprotective Effects of Mebudipine in a Rat Model of Doxorubicin-Induced Heart Failure. سامانه مدیریت نشریات علمی, 1399; 46(2): 136-143. doi: 10.30476/ijms.2019.82057.0

Cardioprotective Effects of Mebudipine in a Rat Model of Doxorubicin-Induced Heart Failure

Iranian Journal of Medical Sciences
مقاله 8، دوره 46، شماره 2، خرداد 2021، صفحه 136-143    اصل مقاله (265.68 K)
نوع مقاله: Original Article(s)
شناسه دیجیتال (DOI): 10.30476/ijms.2019.82057.0
نویسندگان
Ehsan Aali1، 2؛ Habib Ghaznavi3؛ Mohammad Soleiman Soltanpour4؛ Massoud Mahmoudian5؛ Massoumeh Shafiei* 5
1Department of Pharmacology, School of Medicine, Qazvin University of Medical Sciences, Qazvin, Iran
2Gifted and Talented Students Center, Iran University of Medical Sciences, Tehran, Iran
3Department of Pharmacology, Zahedan University of Medical Sciences, Zahedan, Iran
4Department of Medical Laboratory Sciences, School of Paramedical Sciences, Zanjan University of Medical Sciences, Zanjan, Iran
5Department of Pharmacology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran
چکیده
Background: Mebudipine, a dihydropyridine calcium-channel blocker (CCB), shows greater time- and voltage-dependent inhibitory effects than nifedipine. Its significant negative chronotropic effects without having considerable negative inotropic properties may make it a suitable candidate for the pharmacotherapy of heart failure (HF). This study aimed to investigate the possible beneficial action of mebudipine in a rat model of HF.
Methods: The present study carried out in the Department of Pharmacology at the Iran University of Medical Sciences during the years of 2009-2011. An experimental model of HF was induced in male Wistar rats using doxorubicin (DOX). The rats were divided into five groups with seven animals in each group: normal control group, DOX-induced HF control groups, and treatment groups. The animals were administered DOX for 15 days. A consistent deterioration occurred after a four-week rest period. The animals were then treated with intraperitoneal mebudipine (0.5 mg/kg) and intraperitoneal amlodipine (0.35 mg/kg), as well as an equal volume of distilled water for 15 days. The plasma levels of big endothelin-1 (BET-1), creatine kinase-myocardial band (CK-MB), lactate dehydrogenase (LDH), aspartate aminotransferase (AST), and alanine aminotransferase (ALT), as well as the clinical status (heart rate and blood pressure), were assessed before and after treatment. Statistical analysis was performed with SPSS software using parametric and nonparametric ANOVA.
Results: Mebudipine and amlodipine reversed the increased plasma BET-1 values in the treated animals when compared with the HF control group (0.103 and 0.112 vs 0.231 pg/mL, respectively). The increased plasma levels of AST, ALT, CK-MB, and LDH were also reversed in the HF animals that received mebudipine or amlodipine.
Conclusion: The administration of mebudipine to HF animals, akin to amlodipine, palliated the clinical and biochemical signs of the disease in the present study.
The abstract was presented in the Iranian Congress of Physiology and Pharmacology as a poster and published in the Scientific Information Database as a supplement (2015; Vol 22).
کلیدواژه‌ها
Mebudipine؛ Amlodipine؛ Endothelin-1؛ Heart failure؛ Doxorubicin
سایر فایل های مرتبط با مقاله
مراجع
  1. Figueroa MS, Peters JI. Congestive heart failure: Diagnosis, pathophysiology, therapy, and implications for respiratory care. Respir Care. 2006;51:403-12. PubMed PMID: 16563194.
  2. Tocci G, Battistoni A, Passerini J, Musumeci MB, Francia P, Ferrucci A, et al. Calcium channel blockers and hypertension. J Cardiovasc Pharmacol Ther. 2015;20:121-30. doi: 10.1177/1074248414555403. PubMed PMID: 25398848.
  3. Gillum RF. Epidemiology of heart failure in the United States. Am Heart J. 1993;126:1042-7. doi: 10.1016/0002-8703(93)90738-u. PubMed PMID: 8213434.
  4. Bahrami H, Kronmal R, Bluemke DA, Olson J, Shea S, Liu K, et al. Differences in the incidence of congestive heart failure by ethnicity: the multi-ethnic study of atherosclerosis. Arch Intern Med. 2008;168:2138-45. doi: 10.1001/archinte.168.19.2138. PubMed PMID: 18955644; PubMed Central PMCID: PMCPMC3038918.
  5. Ellahham SH, Charlon V, Abassi Z, Calis KA, Choucair WK. Bosentan and the endothelin system in congestive heart failure. Clin Cardiol. 2000;23:803-7. doi: 10.1002/clc.4960231128. PubMed PMID: 11097125; PubMed Central PMCID: PMCPMC6655168.
  6. Krum H, Denver R, Tzanidis A, Martin P. Diagnostic and therapeutic potential of the endothelin system in patients with chronic heart failure. Heart Fail Rev. 2001;6:341-52. doi: 10.1023/a:1011416611765. PubMed PMID: 11447309.
  7. Hoffman A, Abassi ZA, Brodsky S, Ramadan R, Winaver J. Mechanisms of big endothelin-1-induced diuresis and natriuresis : role of ET(B) receptors. Hypertension. 2000;35:732-9. doi: 10.1161/01.hyp.35.3.732. PubMed PMID: 10720587.
  8. Cody RJ, Haas GJ, Binkley PF, Capers Q, Kelley R. Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure. Circulation. 1992;85:504-9. doi: 10.1161/01.cir.85.2.504. PubMed PMID: 1735147.
  9. Stewart DJ, Cernacek P, Costello KB, Rouleau JL. Elevated endothelin-1 in heart failure and loss of normal response to postural change. Circulation. 1992;85:510-7. doi: 10.1161/01.cir.85.2.510. PubMed PMID: 1346510.
  10. Yazaki Y, Yamazaki T. Reversing congestive heart failure with endothelin receptor antagonists. Circulation. 1997;95:1752-4. doi: 10.1161/01.cir.95.7.1752. PubMed PMID: 9107157.
  11. Spieker LE, Noll G, Ruschitzka FT, Luscher TF. Endothelin receptor antagonists in congestive heart failure: a new therapeutic principle for the future? J Am Coll Cardiol. 2001;37:1493-505. doi: 10.1016/s0735-1097(01)01210-4. PubMed PMID: 11345356.
  12. Berger R, Strecker K, Huelsmann M, Moser P, Frey B, Bojic A, et al. Prognostic power of neurohumoral parameters in chronic heart failure depends on clinical stage and observation period. J Heart Lung Transplant. 2003;22:1037-45. doi: 10.1016/s1053-2498(02)00560-0. PubMed PMID: 12957614.
  13. Hulsmann M, Stanek B, Frey B, Sturm B, Putz D, Kos T, et al. Value of cardiopulmonary exercise testing and big endothelin plasma levels to predict short-term prognosis of patients with chronic heart failure. J Am Coll Cardiol. 1998;32:1695-700. doi: 10.1016/s0735-1097(98)00437-9. PubMed PMID: 9822098.
  14. Mahmoudian M, Mirkhani H, Nehardani Z, Ghiaee S. Synthesis and biological activity of two new calcium-channel blockers, mebudipine and dibudipine. J Pharm Pharmacol. 1997;49:1229-33. doi: 10.1111/j.2042-7158.1997.tb06075.x. PubMed PMID: 9466348.
  15. Bucci C, Mamdani MM, Juurlink DN, Tu JV. Dihydropyridine calcium channel blockers and cardiovascular outcomes in elderly patients: a population-based study. Can J Cardiol. 2008;24:629-32. doi: 10.1016/s0828-282x(08)70651-2. PubMed PMID: 18685743; PubMed Central PMCID: PMCPMC2644360.
  16. Aouam K, Berdeaux A. [Dihydropyridines from the first to the fourth generation: better effects and safety]. Therapie. 2003;58:333-9. doi: 10.2515/therapie:2003051. PubMed PMID: 14679672.
  17. Lee SA, Choi HM, Park HJ, Ko SK, Lee HY. Amlodipine and cardiovascular outcomes in hypertensive patients: meta-analysis comparing amlodipine-based versus other antihypertensive therapy. Korean J Intern Med. 2014;29:315-24. doi: 10.3904/kjim.2014.29.3.315. PubMed PMID: 24851066; PubMed Central PMCID: PMCPMC4028521.
  18. Mason RP. Mechanisms of plaque stabilization for the dihydropyridine calcium channel blocker amlodipine: review of the evidence. Atherosclerosis. 2002;165:191-9. doi: 10.1016/s0021-9150(01)00729-8. PubMed PMID: 12417269.
  19. Packer M, O’Connor CM, Ghali JK, Pressler ML, Carson PE, Belkin RN, et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group. N Engl J Med. 1996;335:1107-14. doi: 10.1056/NEJM199610103351504. PubMed PMID: 8813041.
  20. Faizi M, Janahmadi M, Mahmoudian M. The effect of mebudipine and dibudipine, two new Ca2+ channel blockers, in comparison with nifedipine on Ca2+ spikes of F1 neuronal soma membrane in Helix aspersa. Acta Physiol Hung. 2003;90:243-54. doi: 10.1556/APhysiol.90.2003.3.7. PubMed PMID: 14594195.
  21. Mirkhani H, Dirin M, Youssef-Zayeh I. Mechanism of vasoselective action of mebudipine, a new calcium channel blocker. Vascul Pharmacol. 2004;42:23-9. doi: 10.1016/j.vph.2004.12.002. PubMed PMID: 15664884.
  22. Bohlooli S, Mahmoudian M, Skellern GG, Grant MH, Tettey JN. Metabolism of the dihydropyridine calcium channel blockers mebudipine and dibudipine by isolated rat hepatocytes. J Pharm Pharmacol. 2004;56:1469-75. doi: 10.1211/0022357044760. PubMed PMID: 15525456.
  23. Elkayam U. Calcium channel blockers in heart failure. Cardiology. 1998;89:38-46. doi: 10.1159/000047278. PubMed PMID: 9570428.
  24. Daniel WW, Cross CL. Biostatistics: A Foundation for Analysis in the Health Sciences. Ayatollahi SMT, translator. Tehran (Persian): Amirkabir; 1984. Translation of: New York: Wiley.
  25. Kawasaki N, Lee JD, Shimizu H, Ueda T. Long-term 1-carnitine treatment prolongs the survival in rats with adriamycin-induced heart failure. J Card Fail. 1996;2:293-9. doi: 10.1016/s1071-9164(96)80016-9. PubMed PMID: 8989644.
  26. Mirkhani H, Omrani GR, Ghiaee S, Mahmoudian M. Effects of mebudipine and dibudipine, two new calcium-channel blockers, on rat left atrium, rat blood pressure and human internal mammary artery. J Pharm Pharmacol. 1999;51:617-22. doi: 10.1211/0022357991772727. PubMed PMID: 10411222.
  27. Rouzrokh A, Ebrahimi SA, Rahbr-Roshandel N, Mahmoudian M. Effects of mebudipine and dibudipine, two new calcium channel blockers on voltage-activated calcium currents of PC12 cells. Acta Physiol Hung. 2007;94:199-207. doi: 10.1556/APhysiol.94.2007.3.5. PubMed PMID: 17853772.
  28. Pacher R, Stanek B, Hulsmann M, Koller-Strametz J, Berger R, Schuller M, et al. Prognostic impact of big endothelin-1 plasma concentrations compared with invasive hemodynamic evaluation in severe heart failure. J Am Coll Cardiol. 1996;27:633-41. doi: 10.1016/0735-1097(95)00520-x. PubMed PMID: 8606275.
  29. Stanek B, Frey B, Hulsmann M, Koller-Strametz J, Hartter E, Schuller M, et al. Validation of big endothelin plasma levels compared with established neurohumoral markers in patients with severe chronic heart failure. Transplant Proc. 1997;29:595-6. doi: 10.1016/s0041-1345(96)00097-8. PubMed PMID: 9123146.
  30. Omland T, Lie RT, Aakvaag A, Aarsland T, Dickstein K. Plasma endothelin determination as a prognostic indicator of 1-year mortality after acute myocardial infarction. Circulation. 1994;89:1573-9. doi: 10.1161/01.cir.89.4.1573. PubMed PMID: 8149523.
  31. Loffler BM, Jacot-Guillarmod H, Maire JP. Concentrations and ratios of immunoreactive big-endothelin-1 and endothelin-1 in human, rat and rabbit plasma. Biochem Int. 1992;27:755-61. PubMed PMID: 1417908.
  32. Lundblad R, Giercksky KE. Endothelin concentrations in experimental sepsis: profiles of big endothelin and endothelin 1-21 in lethal peritonitis in rats. Eur J Surg. 1995;161:9-16. PubMed PMID: 7727611.
  33. Zhang X, Xu X, Nasjletti A, Hintze TH. Amlodipine enhances NO production induced by an ACE inhibitor through a kinin-mediated mechanism in canine coronary microvessels. J Cardiovasc Pharmacol. 2000;35:195-202. doi: 10.1097/00005344-200002000-00004. PubMed PMID: 10672850.
  34. Donmez G, Derici U, Erbas D, Arinsoy T, Onk A, Sindel S, et al. The effects of losartan and enalapril therapies on the levels of nitric oxide, malondialdehyde, and glutathione in patients with essential hypertension. Jpn J Physiol. 2002;52:435-40. doi: 10.2170/jjphysiol.52.435. PubMed PMID: 12533248.
  35. Kalinowski L, Matys T, Chabielska E, Buczko W, Malinski T. Angiotensin II AT1 receptor antagonists inhibit platelet adhesion and aggregation by nitric oxide release. Hypertension. 2002;40:521-7. doi: 10.1161/01.hyp.0000034745.98129.ec. PubMed PMID: 12364357.
  36. Champagne S, Hittinger L, Heloire F, Suto Y, Sambin L, Crozatier B, et al. Reduced coronary vasodilator responses to amlodipine in pacing-induced heart failure in conscious dogs: role of nitric oxide. Br J Pharmacol. 2002;136:264-70. doi: 10.1038/sj.bjp.0704701. PubMed PMID: 12010775; PubMed Central PMCID: PMCPMC1573341.
  37. Zhang X, Kichuk MR, Mital S, Oz M, Michler R, Nasjletti A, et al. Amlodipine promotes kinin-mediated nitric oxide production in coronary microvessels of failing human hearts. Am J Cardiol. 1999;84:27L-33L. doi: 10.1016/s0002-9149(99)00362-8. PubMed PMID: 10480443.
  38. Kitakaze M, Asanuma H, Takashima S, Minamino T, Ueda Y, Sakata Y, et al. Nifedipine-induced coronary vasodilation in ischemic hearts is attributable to bradykinin- and NO-dependent mechanisms in dogs. Circulation. 2000;101:311-7. doi: 10.1161/01.cir.101.3.311. PubMed PMID: 10645928.
  39. Arhancet GB, Woodard SS, Dietz JD, Garland DJ, Wagner GM, Iyanar K, et al. Stereochemical requirements for the mineralocorticoid receptor antagonist activity of dihydropyridines. J Med Chem. 2010;53:4300-4. doi: 10.1021/jm1002827. PubMed PMID: 20408553.
  40. Goldstein RE, Boccuzzi SJ, Cruess D, Nattel S. Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction. The Adverse Experience Committee; and the Multicenter Diltiazem Postinfarction Research Group. Circulation. 1991;83:52-60. doi: 10.1161/01.cir.83.1.52. PubMed PMID: 1984898.
  41. Francis GS. Calcium channel blockers and congestive heart failure. Circulation. 1991;83:336-8. doi: 10.1161/01.cir.83.1.336. PubMed PMID: 1984891.
آمار
تعداد مشاهده مقاله: 3,586
تعداد دریافت فایل اصل مقاله: 2,332


سامانه مدیریت نشریات علمی. قدرت گرفته از سیناوب